Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

By sjmartinez • April 9, 2025

Daar ES, Orkin C, Sax PE, Hagins D, Pozniak A, Workowski K, Brinson C, Tiraboschi JM, Liu H, Deaton C, Cohen C, Madera S, Hindman JT, Ramgopal M. Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. AIDS Res Ther. 2025 Apr 7;22(1):45. doi: 10.1186/s12981-025-00732-w. PMID: 40197415; PMCID: PMC11978100.

Tags: antiretroviral therapy, Bictegravir, body mass index, dolutegravir, glucose, Harbor UCLA, HIV-1, Infectious Diseases, Publications, Tenofovir alafenamide

Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Castillo DR, Shah P, Tai D, Guo M, Hazeltine M, Guzman S, Park D, Mannan R, Xing Y, Brar G, Raoof M, Eng C, Wu[...]

Women and Herpes Zoster in the United States: Risk and Prevention Management-A Narrative Review

Campos R, Caldera F, Carrico J, Cochrane C, Eltoukhy N, Huang C, Kneller S, Rutland C, Slovis J. Women and Herpes Zoster in the United[...]

Response to the Letter to the Editor Entitled “Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy”

Giri K, Glassock RJ, Fervenza FC. Response to the Letter to the Editor Entitled "Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy". Kidney Int[...]